相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center
Jessica J. Jalbert et al.
ONCOLOGIST (2020)
Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome
Dominique Clement et al.
JOURNAL OF ONCOLOGY (2020)
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up y
M. Pavel et al.
ANNALS OF ONCOLOGY (2020)
Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors
Sara Pusceddu et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors
Debra Patt et al.
JCO CLINICAL CANCER INFORMATICS (2020)
Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide
Nikki McCaffrey et al.
BMC CANCER (2020)
Patient Survey of the Physical, Emotional, and Informational Challenges for Patients Living with Neuroendocrine Tumors
Mohid S. Khan et al.
ONCOLOGY AND THERAPY (2020)
Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors
Andrew J. Klink et al.
ONCOLOGIST (2019)
Management of Diarrhea in Patients With Carcinoid Syndrome
Boris G. Naraev et al.
PANCREAS (2019)
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study
George A. Fisher et al.
ONCOLOGIST (2018)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl
Lowell Anthony et al.
CLINICAL THERAPEUTICS (2017)
Principles of diagnosis and management of neuroendocrine tumours
Michael J. Raphael et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2017)
Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden
Timothy P. Pearman et al.
SUPPORTIVE CARE IN CANCER (2016)
Healthcare and economic impact of diarrhea in patients with carcinoid syndrome
Michael S. Broder et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Complications from carcinoid syndrome: review of the current evidence
Jose Mauricio Mota et al.
ECANCERMEDICALSCIENCE (2016)
Double-Blind, Placebo-Controlled, Randomized Trial of Octreotide in Malignant Bowel Obstruction
David C. Currow et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2015)
Management of intestinal obstruction in advanced malignancy
Henry John Murray Ferguson et al.
ANNALS OF MEDICINE AND SURGERY (2015)
Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study
Jonathan R. Strosberg et al.
ONCOLOGIST (2014)
Clinical Impact of Palliative Treatment Using Octreotide for Inoperable Malignant Bowel Obstruction Caused by Advanced Urological Cancer
Hiroki Kubota et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Improving the Success Rate of Gluteal Intramuscular Injections
April E. Boyd et al.
PANCREAS (2013)
Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)
M. S. Khan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Evaluating the Characteristics and the Management of Patients With Neuroendocrine Tumors Receiving Octreotide LAR During a 6-Year Period
Lowell Anthony et al.
PANCREAS (2011)
Internalized Somatostatin Receptor Subtype 2 in Neuroendocrine Tumors of Octreotide-Treated Patients
Jean Claude Reubi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum
J. Philip Boudreaux et al.
PANCREAS (2010)
From somatostatin to octreotide LAR: evolution of a somatostatin analogue
Lowell Anthony et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients
Eugene A. Woltering et al.
PANCREAS (2008)
Therapeutic options for gastrointestinal carcinoids
Irvin M. Modlin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles
B Astruc et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
K Öberg et al.
ANNALS OF ONCOLOGY (2004)
The pathophysiological consequences of somatostatin receptor internalization and resistance
LJ Hofland et al.
ENDOCRINE REVIEWS (2003)
分享论文
